IDEAYA Biosciences announced updated Phase 1 clinical results for IDE849, an investigational antibody-drug conjugate targeting DLL3, showing strong anti-tumor activity and encouraging overall survival in relapsed small cell lung cancer (SCLC) and other neuroendocrine carcinomas (NECs). The study reported a median overall survival of 17.4 months in second-line SCLC patients and response rates above 50% in both SCLC and NEC groups, including patients with brain metastases. Safety data showed manageable treatment-related adverse events, with low discontinuation rates. Following positive FDA meetings, IDEAYA plans to initiate two Phase 3 trials for IDE849 in extensive-stage SCLC and NEC, with ongoing evaluation of a first-line SCLC study design.
IDE849 updated Phase 1 results provide context for readers. For those following health stocks, 51 of 150 US health-sector stocks rose and 90 fell on Pluang as of Oct 23, 2026 17:11 WIB. Notable movers include BRKR at USD 56.00 down 2.29%, INO at USD 0.86 up 2.10% with 73% sell orders, and LFST at USD 12.33 down 1.83%.
Global zinc supply is expected to fall short by 88,000 tonnes in 2026 amid declining mine production, while tin demand is projected to outpace supply growth through 2035. This has renewed exploration in historic polymetallic mining districts in the U...
Avacta Therapeutics presented positive preclinical and early clinical data for AVA6103, a novel peptide-drug conjugate targeting FAP-positive tumors resistant to Enhertu. AVA6103 demonstrated superior tumor control and prolonged drug release in precl...
Obra Capital has closed its fifth Collateralized Loan Obligation (CLO) offering, raising $403.6 million. This deal brings the firm's total CLO issuance to more than $2 billion across five deals in less than two years, demonstrating strong investor co...
ImPact Biotech reported positive early results from its Phase 1 trial of Padeliporfin VTP in patients with locally advanced, unresectable pancreatic cancer. Of 12 patients treated, 75% have undergone or are scheduled for surgery, with over half achie...
eSoftware Associates has introduced a free five-minute AI readiness assessment to help regulated organizations identify and prioritize security risks related to sensitive file access in Microsoft 365 before deploying Copilot. The assessment highlight...
